The treatment of aggressive prolactinomas with everolimus.
Aggressive pituitary adenoma
Pituitary carcinoma
Prolactinoma
Targeted therapy
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
accepted:
03
07
2023
medline:
3
8
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
ppublish
Résumé
Aggressive prolactinomas are life-limiting tumors without a standard of care treatment option after the oral alkylator, temozolomide, fails to provide tumor control. We reviewed an institutional database of pituitary tumors for patients with aggressive prolactinomas who progressed following treatment with a dopamine receptor agonist, radiotherapy and temozolomide. Within this cohort, we identified four patients who were treated with everolimus and we report their response to this therapy. Treatment response was determined by a neuroradiologist, who manually performed volumetric assessment and determined treatment response by Response Assessments in Neuro-Oncology (RANO) criteria. Three of four patients who were treated with everolimus had a biochemical response to therapy and all patients derived a clinically meaningful benefit based upon suppression of tumor growth. While the best overall response as assessed by RANO criteria was stable disease for the four patients, a minor regression in tumor size was appreciated in two of the four patients. Everolimus is an active agent in the treatment of prolactinomas that warrants further investigation.
Identifiants
pubmed: 37428396
doi: 10.1007/s11102-023-01340-5
pii: 10.1007/s11102-023-01340-5
doi:
Substances chimiques
Everolimus
9HW64Q8G6G
Temozolomide
YF1K15M17Y
Dopamine Agonists
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
474-481Subventions
Organisme : NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Melmed S et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288. https://doi.org/10.1210/jc.2010-1692
doi: 10.1210/jc.2010-1692
pubmed: 21296991
McCormack A et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178(3):265–276. https://doi.org/10.1530/EJE-17-0933
doi: 10.1530/EJE-17-0933
pubmed: 29330228
Bengtsson D et al (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689–1698. https://doi.org/10.1210/jc.2014-4350
doi: 10.1210/jc.2014-4350
pubmed: 25646794
Burman P et al (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187(4):593–605. https://doi.org/10.1530/EJE-22-0440
doi: 10.1530/EJE-22-0440
pubmed: 36018781
pmcid: 9513638
Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523. https://doi.org/10.1056/NEJMoa1009290
doi: 10.1056/NEJMoa1009290
pubmed: 21306238
pmcid: 4208619
Baselga J et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. https://doi.org/10.1056/NEJMoa1109653
doi: 10.1056/NEJMoa1109653
pubmed: 22149876
Monsalves E et al (2014) The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr Relat Cancer 21(4):R331–R344. https://doi.org/10.1530/ERC-14-0188
doi: 10.1530/ERC-14-0188
pubmed: 25052915
Zhang D et al (2019) Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab 104(6):1929–1936. https://doi.org/10.1210/jc.2018-02461
doi: 10.1210/jc.2018-02461
pubmed: 30624667
Wen PY et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972. https://doi.org/10.1200/JCO.2009.26.3541
doi: 10.1200/JCO.2009.26.3541
pubmed: 20231676
Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228–243. https://doi.org/10.1007/s12022-017-9498-z
doi: 10.1007/s12022-017-9498-z
pubmed: 28766057
Asa SL et al (2022) Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 33(1):6–26. https://doi.org/10.1007/s12022-022-09703-7
doi: 10.1007/s12022-022-09703-7
pubmed: 35291028
Trouillas J et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135. https://doi.org/10.1007/s00401-013-1084-y
doi: 10.1007/s00401-013-1084-y
pubmed: 23400299
Motzer RJ et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116(18):4256–4265. https://doi.org/10.1002/cncr.25219
doi: 10.1002/cncr.25219
pubmed: 20549832
White DA et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182(3):396–403. https://doi.org/10.1164/rccm.200911-1720OC
doi: 10.1164/rccm.200911-1720OC
pubmed: 20194812
Rugo HS et al (2017) Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol 18(5):654–662. https://doi.org/10.1016/S1470-2045(17)30109-2
doi: 10.1016/S1470-2045(17)30109-2
pubmed: 28314691
Cooper O et al (2014) Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine 46(2):318–327. https://doi.org/10.1007/s12020-013-0093-x
doi: 10.1007/s12020-013-0093-x
pubmed: 24287797
Ben-Jonathan N et al (2009) Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs. Endocrinology 150(2):795–802. https://doi.org/10.1210/en.2008-0756
doi: 10.1210/en.2008-0756
pubmed: 18832099
Fukuoka H et al (2011) HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol 25(1):92–103. https://doi.org/10.1210/me.2010-0353
doi: 10.1210/me.2010-0353
pubmed: 21106881
Cooper O et al (2021) EGFR/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J Clin Endocrinol Metab 106(2):e917–e925. https://doi.org/10.1210/clinem/dgaa805
doi: 10.1210/clinem/dgaa805
pubmed: 33150390
Gadgeel SM et al (2013) Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol 72(5):1089–1096. https://doi.org/10.1007/s00280-013-2297-4
doi: 10.1007/s00280-013-2297-4
pubmed: 24057042
pmcid: 4072025